Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8368700 | 0.84 | CTSS (0.38) | DGAT2KMT2ATRPA1MAPK1L3MBTL1 | |
| SCHEMBL23636217 | 0.83 | DGAT2 (0.35) | DGAT2KMT2ATRPA1MAPK1L3MBTL1 | |
| SCHEMBL5849380 | 0.81 | DGAT2 (0.37) | DGAT2KMT2AMAPK1L3MBTL1MAPT | |
| SCHEMBL16043434 | 0.80 | DGAT2 (0.40) | DGAT2ATM | |
| SCHEMBL25836737 | 0.78 | CYP2D6 (0.39) | KMT2ATSHRHSD17B10TRPA1MAPK1 | |
| SCHEMBL21536759 | 0.78 | DGAT2 (0.36) | DGAT2KMT2ATSHRMAPK1L3MBTL1 | |
| SCHEMBL25836755 | 0.77 | KMT2A (0.38) | KMT2ATSHRHSD17B10TRPA1MAPK1 | |
| Oxalic Acid SCHEMBL7028461 | 0.77 | DGAT2 (0.35) | DGAT2ATM | |
| SCHEMBL10928236 | 0.74 | DGAT2 (0.34) | DGAT2MAPK1L3MBTL1MAPTATM | |
| SCHEMBL13650201 | 0.74 | ITGB3 (0.45) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | DGAT2 1524/4885KMT2A 2610/4885TSHR 4401/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | DGAT2 1524/4885KMT2A 2610/4885TSHR 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.